Updated 2025 ASCIA Action Plans for Anaphylaxis
ASCIA has developed 2025 versions of red ASCIA Action Plans for Anaphylaxis and orange ASCIA First Aid Plans for Anaphylaxis, in response to changes regarding adrenaline (epinephrine) devices:
- Anapen® 500 is listed on the general and Anapen® versions of ASCIA Action and First Aid Plans, as Anapen® 150 and Anapen® 300 are no longer available in Australia.
- The word “injector” has been replaced with “device” to enable ASCIA plans to remain relevant when other types of adrenaline devices become available in Australia and New Zealand.
The 2025 versions of ASCIA plans are now available on the ASCIA website
Read more about the changes here
ASCIA anaphylaxis e-training courses will be updated in January 2025 with the changes noted above.
New ASCIA Anaphylaxis Training Refresher Video
ASCIA has worked with a world leading video production company to adapt ASCIA Anaphylaxis Refresher e-training for schools, children’s education/care and community into a short, accessible video, that takes less than 20 minutes to watch.
This video includes the 2025 versions of ASCIA Action Plans and ASCIA First Aid Plans.
The video can be accessed here
New ASCIA FAQ for Patients and Carers
The following new ASCIA Frequently Asked Questions (FAQ) for patients and carers have been developed in response to requests from ASCIA members for information on these topics:
* These non-allergic conditions can be mistaken for other conditions, but require different treatments:
- Vocal cord dysfunction can be confused with anaphylaxis or asthma
- Non-allergic rhinitis can appear to be allergic rhinitis
ASCIA 2024Â Conference Updates
ASCIA 2024 Conference poster abstracts have now been published in the online Internal Medicine Journal (IMJ) and are available open access via the ASCIA website
The ASCIA 2024 Conference was a hybrid conference, which enables on-demand viewing of sessions for all registered delegates for 6 months after the conference. Read more here
National Allergy Council Projects Allocated to ASCIA
ASCIA’s role in the National Allergy Council includes the following projects, supported by funding from the Australian government:
- Schools/Childcare project – to provide and facilitate anaphylaxis and allergy education and training for people working in schools, children’s education/care services and the community.
- Shared Care for Allergy project - to provide and facilitate anaphylaxis and allergy education and training for health professionals, and to promote credible patient/carer support organisations.
- Drug (Medication) Allergy project - to provide and facilitate drug (medication) allergy education and training for health professionals.
An update on achievements for activities allocated to ASCIA in 2024 and activities due for completion in 2025 is available on the ASCIA website
Research Opportunities
Responses to an allergic rhinitis research survey are due by 30 November 2024 - Read more here
The ASCIA website has a dedicated research webpage with links to research studies, including the following recent additions:
- ANCA-Associated Vasculitis Survey for Clinicians
- Management of Atopic Dermatitis (AD) - 2 hours of CPD for Clinicians
Recent ASCIA Immunology Updates
News update - Shingrix Vaccine to Prevent Shingles - September 2024 Update
New ASCIA Clinical Care Standard – Inborn Errors of Immunity
New ASCIA Sjögren’s Disease FAQ for patients and carers
New Activity Based Funding for subcutaneous immunoglobulin (SCIg) therapy
New treatment for severe lupus listed on PBS 1 July 2024
Regularly Updated ASCIA Webpages
The following ASCIA webpages are regularly updated:
Referrals
ASCIA Reports
Locate a Specialist
ASCIA Submissions
Allergy/Immunology Positions
Allergy and Immunology Research
Conference, Meetings and Events Calendar
Â
ASCIA gratefully acknowledges the generous support of all sponsors listed on the ASCIA website www.allergy.org.au/about-ascia/sponsors
